Long-term results and prognostic factors in patients wi

Cancer

55, 794-804

DOI: 10.1002/1097-0142(19850215)55:4<794::aid-cncr2820550418>3.0.co;2-z

Citation Report

#	Article	IF	CITATIONS
1	How Should We Proceed When a Thyroid Nodule is Palpated ?. Acta Clinica Belgica, 1985, 40, 336-337.	0.5	0
2	External radiotherapy in thyroid cancers. Cancer, 1985, 55, 2062-2071.	2.0	204
3	Long-Term Results of Treatment of 283 Patients with Lung and Bone Metastases from Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 960-967.	1.8	486
4	SCHWANN CELL EXPRESSION OF HLA-DR ANTIGEN IN PERIPHERAL NEUROPATHIES. Lancet, The, 1986, 328, 1282-1283.	6.3	18
5	NODAL METASTASES FROM PAPILLARY THYROID CARCINOMA. Lancet, The, 1986, 328, 1283.	6.3	10
6	Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome. Mayo Clinic Proceedings, 1986, 61, 978-996.	1.4	592
7	Thyrotropin Secretion in Thyrotoxic and Thyroxine-Treated Patients: Assessement by a Sensitivie Immunoenzymometric Assay*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 349-355.	1.8	66
8	Survival and Prognostic Factors in Thyroid Carcinoma. Acta Radiologica Oncology, 1986, 25, 243-248.	0.5	35
9	Multifactorial analysis of survival in thyroid cancer: Pitfalls of applying the results of published studies to another population. Cancer, 1986, 58, 1749-1755.	2.0	76
10	Operative strategy for thyroid cancer. Is total thyroidectomy worth the price?. Cancer, 1986, 58, 2320-2328.	2.0	98
11	Thyroid carcinoma in children and adolescents. Cancer, 1986, 58, 2329-2332.	2.0	57
12	Influence of cellular DNA content on survival in differentiated thyroid cancer. Cancer, 1986, 58, 2462-2467.	2.0	118
13	Differentiated Thyroid Carcinoma in Childhood: Long Term Follow-Up of 72 Patients. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 1088-1094.	1.8	243
15	Papillary and follicular thyroid cancer. American Journal of Medicine, 1987, 83, 479-488.	0.6	346
16	Surgical treatment of invasion of the upper aerodigestive tract by well-differentiated thyroid carcinoma. American Journal of Surgery, 1987, 154, 363-367.	0.9	54
19	Mortality from papillary thyroid carcinoma: A case-control study of 56 lethal cases. Cancer, 1988, 62, 1381-1388.	2.0	77
20	Prognostic value of nuclear DNA content in papillary and follicular thyroid cancer. World Journal of Surgery, 1988, 12, 503-507.	0.8	42
21	Modified neck dissection for patients with nonadvanced, differentiated carcinoma of the thyroid. World Journal of Surgery, 1988, 12, 825-828.	0.8	57

#	Article	IF	CITATIONS
22	Deaths due to differentiated thyroid cancer: A 46-year perspective. World Journal of Surgery, 1988, 12, 623-628.	0.8	45
23	Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas. British Journal of Cancer, 1988, 57, 43-47.	2.9	80
24	Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. International Journal of Radiation Oncology Biology Physics, 1988, 14, 1063-1075.	0.4	271
25	Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. European Journal of Cancer & Clinical Oncology, 1988, 24, 331-337.	0.9	88
26	Follow-up of patients with differentiated thyroid carcinoma. Experience at Institut Gustave-Roussy, Villejuif. European Journal of Cancer & Clinical Oncology, 1988, 24, 345-350.	0.9	30
27	Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. European Journal of Cancer & Clinical Oncology, 1988, 24, 287-292.	0.9	51
28	THYROGLOBULIN LEVEL HELPS TO PREDICT RECURRENCE AFTER LOBO-ISTHMUSECTOMY IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA. Lancet, The, 1988, 331, 52-53.	6.3	13
29	Prognostic value of morphometry in papillary thyroid carcinoma. , 1988, , .		2
30	Early Metastatic Cancer of Unknown Primary Origin at Presentation. Archives of Internal Medicine, 1988, 148, 2035.	4.3	112
31	Thyroid cancer in Iceland 1955-1984. European Journal of Endocrinology, 1988, 118, 566-572.	1.9	47
32	Cellular DNA Pattern, S-Phase Frequency and Survival in Papillary Thyroid Cancer. Acta Oncológica, 1988, 27, 329-333.	0.8	27
33	The Place of External Radiation Therapy for Differentiated and Undifferentiated Thyroid Carcinoma. Progress in Surgery, 1988, 19, 147-162.	0.0	2
34	Favorable Long Term Results in Patients with Small Differentiated Thyroid Cancer not Treated with Radioiodine. Tumori, 1989, 75, 57-59.	0.6	1
35	Radiation Therapy of Head and Neck Cancer. Medical Radiology, 1989, , .	0.0	9
36	Prognostic Factors in Patients Dying of Well-Differentiated Thyroid Cancer. JAMA Otolaryngology, 1989, 115, 326-330.	1.5	28
37	Metastatic papillary carcinoma of the thyroid: The significance of extranodal extension. Head and Neck, 1989, 11, 242-246.	0.9	39
38	Immunogenetic and immunologic studies of differentiated thyroid cancer. Cancer, 1989, 63, 1318-1326.	2.0	36
39	Survival and prognostic factors in differentiated thyroid cancer – a multivariate analysis of 1,055 cases. British Journal of Cancer, 1989, 59, 231-235.	2.9	59

#	ARTICLE	IF	CITATIONS
40	Prognosis and morbidity after total thyroidectomy for papillary, follicular and medullary thyroid cancer. European Journal of Cancer & Clinical Oncology, 1989, 25, 1317-1323.	0.9	32
41	Prognostic value of morphometry in papillary thyroid carcinoma. Human Pathology, 1989, 20, 215-218.	1.1	29
42	Differentiated Follicle-Derived Thyroid Carcinoma in Children. Acta Paediatrica, International Journal of Paediatrics, 1989, 78, 419-425.	0.7	28
43	Thyroid cancer: A computerâ€assisted review of 5287 cases. Otolaryngology - Head and Neck Surgery, 1990, 102, 51-65.	1.1	70
44	Second Primary Tumors Following Thyroid Cancer a Swedish Record-Linkage Study. Acta Oncológica, 1990, 29, 869-873.	0.8	28
45	Descriptive epidemiology of thyroid cancer in the Swiss Canton of Vaud. Journal of Cancer Research and Clinical Oncology, 1990, 116, 639-647.	1.2	27
46	Papillary thyroid carcinoma: The new, age-related TNM classification system in a retrospective analysis of 199 patients. World Journal of Surgery, 1990, 14, 837-841.	0.8	58
48	Surgery in the Treatment of Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 1990, 19, 663-683.	1.2	27
49	Ablative Radioactive Iodine Therapy for Apparently Localized Thyroid Carcinoma: A Decision Analytic Perspective. Endocrinology and Metabolism Clinics of North America, 1990, 19, 741-760.	1.2	86
50	Follicular and HÃ \P rthle Cell Carcinoma of the Thyroid. Endocrinology and Metabolism Clinics of North America, 1990, 19, 577-591.	1.2	82
51	Papillary Thyroid Carcinoma. Endocrinology and Metabolism Clinics of North America, 1990, 19, 545-576.	1.2	442
52	Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy. Tumori, 1990, 76, 480-483.	0.6	96
53	Natural History, Treatment, and Course of Papillary Thyroid Carcinoma*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 414-424.	1.8	970
54	Pediatric Thyroid Cancer. Pediatric Pathology, 1990, 10, 877-893.	0.5	20
55	Follicular Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome. Mayo Clinic Proceedings, 1991, 66, 11-22.	1.4	549
56	Treating Differentiated Thyroid Carcinoma: Where Do We Draw the Line?. Mayo Clinic Proceedings, 1991, 66, 105-111.	1.4	85
57	Papillary thyroid carcinoma: Occurrence and types of lymph node metastases. Journal of Endocrinological Investigation, 1991, 14, 543-549.	1.8	25
58	Prospective management of nodal metastases in differentiated thyroid cancer. American Journal of Surgery, 1991, 162, 353-356.	0.9	150

#	Article	IF	CITATIONS
59	Distant Metastases in Differentiated Thyroid Cancer: Long-term Results of Radioiodine Treatment and Statistical Analysis of Prognostic Factors in 214 Patients. Tumori, 1991, 77, 432-436.	0.6	75
60	Thyroid Cancer: A Lethal Endocrine Neoplasm. Annals of Internal Medicine, 1991, 115, 133-147.	2.0	220
61	Squamous Cell Carcinoma of the Upper Aerodigestive Tract Associated With WellDifferentiated Carcinoma of the Thyroid Gland. Laryngoscope, 1991, 101, 421-424.	1.1	23
62	The scientific bases of cancer management: at the interface between fundamental research and clinical practice. Journal of Cancer Research and Clinical Oncology, 1991, 117, 275-289.	1.2	3
63	Prognostic indices for tumor relapse and tumor mortality in follicular thyroid carcinoma. Cancer, 1991, 67, 1903-1911.	2.0	82
64	Differentiated thyroid carcinomas in children and adolescents. Cancer, 1991, 67, 2186-2190.	2.0	95
65	Prognostic factors in papillary carcinoma of the thyroid. Cancer, 1991, 68, 324-330.	2.0	86
66	Follicular carcinoma of the thyroid. Journal of Surgical Oncology, 1991, 7, 87-91.	1.4	7
67	Role of thyroid stimulating hormone suppression in the management of thyroid cancer. Journal of Surgical Oncology, 1991, 7, 115-119.	1.4	6
68	Papillary Neoplasms of the Thyroid: <i>Pathologic and Prognostic Features</i> Clinical Pathology, 1992, 97, 426-434.	0.4	125
69	The role of local treatment in the cure of cancer. European Journal of Cancer, 1992, 28, 2061-2069.	1.3	51
70	Issues and Epidemiological Evidence regarding Radiation-Induced Thyroid Cancer. Radiation Research, 1992, 131, 98.	0.7	226
71	Management of local recurrence in well-differentiated thyroid carcinoma. Journal of Surgical Research, 1992, 52, 113-117.	0.8	20
72	Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. American Journal of Surgery, 1992, 164, 578-581.	0.9	135
73	Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. American Journal of Surgery, 1992, 164, 671-676.	0.9	107
74	Outcome of pregnancy following treatment of well-differentiated thyroid cancer with 131iodine. BJOG: an International Journal of Obstetrics and Gynaecology, 1992, 99, 1021-1024.	1.1	14
75	Papillary thyroid carcinoma in Kanazawa, Japan: prognostic significance of histological subtypes. Histopathology, 1992, 20, 243-250.	1.6	62
76	Differentiated thyroid carcinomas: The relevance of various pathological features for tumour classification and prediction of tumour progress. Virchows Archiv A, Pathological Anatomy and Histopathology, 1992, 421, 17-23.	1.4	30

#	Article	IF	Citations
77	Treatment of Thyroid Carcinoma. Laryngoscope, 1992, 102, 486-491.	1.1	10
78	The usefulness of serum thyroglobulin in the follow-up of differentiated thyroid carcinoma in children. Medical and Pediatric Oncology, 1992, 20, 201-208.	1.0	25
79	Proliferative activity in thyroid tumors. Cancer, 1992, 69, 2548-2552.	2.0	23
80	An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma. Recognition of lethal and favorable prognostic types. Cancer, 1992, 70, 2326-2333.	2.0	43
81	Protein kinase C activity in human thyroid carcinoma and adenoma. Cancer, 1992, 70, 2918-2922.	2.0	18
82	Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer, 1993, 71, 1348-1352.	2.0	139
83	Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies. Cancer, 1993, 71, 2807-2812.	2.0	64
84	Estrogen receptors and cathepsin d in human thyroid tissue. Cancer, 1993, 72, 1991-1996.	2.0	47
85	Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer, 1993, 72, 2680-2685.	2.0	139
86	Papillary thyroid cancer in Mexico: Review of 409 cases. Head and Neck, 1993, 15, 537-545.	0.9	10
87	Recurrence-associated mortality in patients with differentiated thyroid carcinoma. Journal of Surgical Oncology, 1993, 52, 164-168.	0.8	13
88	Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 192-4.	2.2	63
89	Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer, 1993, 68, 808-812.	2.9	56
90	Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis. Clinical Endocrinology, 1993, 39, 269-274.	1.2	49
91	Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiotherapy and Oncology, 1993, 28, 16-26.	0.3	64
92	Metastatic thyroid carcinoma of the adrenal gland. Journal of Endocrinological Investigation, 1993, 16, 139-141.	1.8	25
93	Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer, 1993, 29, 44-51.	1.3	85
94	MARKERS OF CELL-PROLIFERATION AS PROGNOSTIC FACTORS IN DIFFERENTIATED THYROID-CANCER. International Journal of Oncology, 1993, 3, 1077-81.	1.4	0

#	Article	IF	CITATIONS
95	The Role of Total Laryngectomy in the Management of Intraluminal Upper Airway Invasion by Well-Differentiated Thyroid Carcinoma. Ear, Nose and Throat Journal, 1994, 73, 659-662.	0.4	17
96	Childhood Thyroid Cancer. JAMA Pediatrics, 1994, 148, 260.	3.6	56
97	THYROID-CANCER - SOME ASPECTS OF EPIDEMIOLOGY AND ETIOLOGIC FACTORS, PATHOLOGICAL FEATURES AND TUMOR BIOLOGY. International Journal of Oncology, 1994, 4, 931-42.	1.4	1
98	Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma Journal of Clinical Endocrinology and Metabolism, 1994, 78, 629-634.	1.8	148
99	Multivariate analysis of risk factors influencing survival in 110 ethnic Chinese with papillary thyroid cancer. World Journal of Surgery, 1994, 18, 547-550.	0.8	17
100	Classification of papillary cancer of the thyroid based on prognosis. World Journal of Surgery, 1994, 18, 552-557.	0.8	101
101	Thyroid cancer treated in chang gung memorial hospital (northern taiwan) during the period 1979–1992: Clinical presentation, pathological finding, analysis of prognostic variables, and results of treatment. Journal of Surgical Oncology, 1994, 57, 252-260.	0.8	23
102	Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer, 1994, 73, 424-431.	2.0	177
103	Follicular carcinoma of the thyroid. Head and Neck, 1994, 16, 533-538.	0.9	47
104	Papillary Thyroid Carcinoma. Laryngoscope, 1994, 104, 747???751.	1.1	16
105	Analysis of risk of death from differentiated thyroid cancer. Radiotherapy and Oncology, 1994, 31, 207-212.	0.3	10
106	Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. European Journal of Cancer, 1994, 30, 733-739.	1.3	100
107	Variable Activity of Protein Tyrosine Kinase in Apparently Normal Thyroid Glands. Cancer Investigation, 1994, 12, 26-32.	0.6	4
108	Outcome of 249 patients attending a nuclear medicine department with well differentiated thyroid cancer; a 23 year review. British Journal of Radiology, 1994, 67, 283-291.	1.0	39
109	Primary thyroid carcinoma in children: A retrospective study of 20 patients. Medical and Pediatric Oncology, 1995, 24, 13-17.	1.0	35
110	Therapeutic implications of prognostic factors in differentiated carcinoma of the thyroid gland. Journal of Surgical Oncology, 1995, 11, 246-255.	1.4	26
111	Metastases to the regional lymph nodes, lymph node recurrence, and distant metastases in nonadvanced papillary thyroid carcinoma. Surgery Today, 1995, 25, 324-328.	0.7	40
112	Prognostic factors associated with differentiated thyroid cancer. Surgery Today, 1995, 25, 778-782.	0.7	18

#	Article	IF	Citations
113	Current Primary Surgery of Thyroid Carcinoma. Oncology Research and Treatment, 1995, 18, 8-15.	0.8	3
114	Long-Term Relapses in Breast Cancer Patients (Estrogen Receptor Status). Tumori, 1995, 81, 265-267.	0.6	2
115	Diagnosis and Management of Thyroid Cancer. Cancer Control, 1995, 2, 107327489500200.	0.7	0
116	Follicular Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 1995, 24, 761-801.	1.2	178
117	Papillary Thyroid Carcinoma. Endocrinology and Metabolism Clinics of North America, 1995, 24, 711-760.	1.2	121
118	Antitumor actions of interferon-gamma and interleukin-1 beta on human papillary thyroid carcinoma cell lines Journal of Clinical Endocrinology and Metabolism, 1995, 80, 1664-1669.	1.8	29
119	Morbidity and mortality in follicular thyroid cancer Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2946-2953.	1.8	104
120	Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery, 1995, 118, 1131-1138.	1.0	251
121	THYROID CANCER IN CHILDREN, PREGNANT WOMEN, AND PATIENTS WITH GRAVES' DISEASE. Endocrinology and Metabolism Clinics of North America, 1996, 25, 27-48.	1.2	63
122	Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery, 1996, 119, 568-575.	1.0	33
123	Well-differentiated thyroid carcinoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 1996, 17, 401-406.	0.6	24
124	Expression of ICAM-1 in distant metastatic thyroid carcinoma. Journal of Endocrinological Investigation, 1996, 19, 183-185.	1.8	5
125	Thyroid Cancer Nodal Metastases: Biologic Significance and Therapeutic Considerations. Surgical Oncology Clinics of North America, 1996, 5, 43-63.	0.6	342
126	Needle aspiration techniques in preoperative selection of patients with thyroid nodules: a long-term study Journal of Clinical Oncology, 1996, 14, 1704-1712.	0.8	77
127	Papillary and follicular thyroid carcinoma: the treatment results of 357 patients at the National Kyushu Cancer Centre of Japan. Journal of Laryngology and Otology, 1996, 110, 657-662.	0.4	15
128	Thyroid cancer: A review of treatment and follow-up. Annals of Nuclear Medicine, 1996, 10, 1-7.	1.2	10
129	Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy., 1996, 78, 493-501.		84
130	Impact of lymph node metastasis in differentiated carcinoma of the thyroid: A matched-pair analysis. , 1996, 18, 127-132.		275

#	Article	IF	CITATIONS
131	Role of radioiodine in the treatment of local thyroid cancer. International Journal of Radiation Oncology Biology Physics, 1996, 36, 263-265.	0.4	6
132	Brain metastases in patients with differentiated thyroid carcinoma. Clinical Oncology, 1996, 8, 327-330.	0.6	33
133	Follicular thyroid cancer. International Journal of Oncology, 1996, 8, 969-76.	1.4	1
134	Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2607-2612.	1.8	44
135	Cancer in adolescence. British Medical Bulletin, 1996, 52, 887-897.	2.7	73
136	Nuclear DNA Content of the Tall Cell Variant of Papillary Carcinoma of the Thyroid Gland. Annals of Otology, Rhinology and Laryngology, 1996, 105, 713-715.	0.6	1
137	Results of External Beam Radiotherapy in Patients With Well Differentiated Thyroid Carcinoma. Japanese Journal of Clinical Oncology, 1997, 27, 244-247.	0.6	35
138	Survival chance in papillary thyroid cancer in Hungary: individual survival probability estimation using the Markov method. Radiotherapy and Oncology, 1997, 44, 203-212.	0.3	11
139	Modified neck dissection in the treatment of differentiated thyroid carcinoma. European Journal of Surgical Oncology, 1997, 23, 286-288.	0.5	6
140	Comparison of nuclear DNA content in locally invasive and noninvasive papillary carcinoma of the thyroid gland. Otolaryngology - Head and Neck Surgery, 1997, 117, 501-503.	1.1	7
141	Factors that predict metastasis of papillary and follicular thyroid cancers in Taiwan. Otolaryngology - Head and Neck Surgery, 1997, 116, 475-482.	1.1	15
142	Prognostic Factors in Thyroid Carcinoma. Surgical Oncology Clinics of North America, 1997, 6, 555-598.	0.6	48
143	Splenomegaly as the First Manifestation of Thyroid Cancer Metastases. Tumori, 1997, 83, 779-782.	0.6	13
144	Postoperative outcome of insufficient surgery for small differentiated thyroid carcinoma. Surgery Today, 1997, 27, 491-494.	0.7	1
145	Thyroid cancer in children: Report of three cases and a review of the Japanese literature. Surgery Today, 1997, 27, 961-965.	0.7	2
147	Prognostic factors in patients with recurrent differentiated thyroid carcinoma., 1997, 64, 202-206.		12
148	Prognostic factors for thyroid carcinoma. , 1997, 79, 564-573.		703
149	Prognostic Factors in Papillary and Follicular Thyroid Carcinomas. Laryngoscope, 1998, 108, 243-249.	1.1	37

#	Article	IF	CITATIONS
150	The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer, 1998, 82, 375-388.	2.0	351
151	Microcarcinoma of the thyroid gland. , 1998, 83, 553-559.		339
152	Therapeutic strategies and long-term results in differentiated thyroid cancer., 1998, 67, 52-59.		15
153	Prognostic factors in differentiated thyroid carcinoma: A multivariate analysis of 234 consecutive patients., 1998, 68, 237-241.		48
154	Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clinical Endocrinology, 1998, 49, 619-628.	1.2	211
155	Trends in treatment and long-term survival of thyroid cancer in Southeastern Netherlands, 1960–1992. European Journal of Cancer, 1998, 34, 1235-1241.	1.3	26
156	Papillary and Follicular Thyroid Carcinoma. New England Journal of Medicine, 1998, 338, 297-306.	13.9	1,422
157	Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2675-2680.	1.8	127
158	Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4195-4199.	1.8	133
159	Sentinel Lymphadenectomy in Thyroid Malignant Neoplasmsâ€"Invited Commentary. Archives of Surgery, 1998, 133, 292.	2.3	0
160	Sentinel Lymphadenectomy in Thyroid Malignant Neoplasms. Archives of Surgery, 1998, 133, 288.	2.3	189
161	Papillary Thyroid Carcinoma. Archives of Surgery, 1998, 133, 276-80.	2.3	190
162	Use of Radioactive Iodine in Patients with Papillary and Follicular Thyroid Cancer: Towards A Selective Approach. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4201-4203.	1.8	13
163	Changing Trends and Prognoses for Patients With Papillary Thyroid Cancer. Archives of Surgery, 1998, 133, 1058.	2.3	24
164	Management of Follicular and HÃ $^{1}\!\!4$ rthle Cell Neoplasms of the Thyroid Gland. Surgical Oncology Clinics of North America, 1998, 7, 893-910.	0.6	39
165	Role of Thyroglobulin Measurement in Fine-Needle Aspiration Biopsies of Cervical Lymph Nodes in Patients with Differentiated Thyroid Cancer. Thyroid, 1999, 9, 105-111.	2.4	158
166	Multiple Primary Cancers of the Esophagus and Thyroid Gland. Japanese Journal of Clinical Oncology, 1999, 29, 349-352.	0.6	10
167	Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma. European Journal of Endocrinology, 1999, 141, 460-467.	1.9	17

#	Article	IF	CITATIONS
168	Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases Endocrine-Related Cancer, 1999, 6, 109-115.	1.6	47
169	Differentiated thyroid cancer: a retrospective analysis of 832 cases from Greece. Clinical Endocrinology, 1999, 50, 643-654.	1.2	28
170	Thyroglobulin Antibodies in Differentiated Thyroid Cancer. Clinical Oncology, 1999, 11, 240-244.	0.6	51
171	Thyroid Cancer in Wales 1985–1996: A Cancer Registry-Based Study. Clinical Oncology, 1999, 11, 245-251.	0.6	23
172	Characteristics and prognostic factors in patients with differentiated thyroid cancer who underwent a total or subtotal thyroidectomy: Surgical approach for high-risk patients. Surgery Today, 1999, 29, 200-203.	0.7	13
173	Apoptosis and proliferative activity in thyroid tumors. Surgery Today, 1999, 29, 204-208.	0.7	31
174	Surveillance of patients to detect recurrent thyroid carcinoma. , 1999, 85, 945-951.		43
175	Extracapsular invasion of lymph node metastasis. , 1999, 86, 842-849.		152
176	Prognostic factors in follicular carcinoma of the thyroidâ€"a multivariate survival analysis. European Journal of Surgical Oncology, 1999, 25, 599-605.	0.5	46
177	Classification and treatment of follicular thyroid neoplasms are discordant between and within medical specialties. Surgery, 1999, 126, 1063-1069.	1.0	9
178	Predictive factors for node involvement in papillary thyroid carcinoma. Univariate and multivariate analyses. European Journal of Cancer, 1999, 35, 420-423.	1.3	45
179	Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma. Journal of Pediatric Surgery, 1999, 34, 1799-1804.	0.8	65
180	Thyroid lung metastasis diagnosed 47 years after thyroidectomy11The views expressed in this article are those of the author and do not reflect the official policy or position of the Department of Navy, Department of Defense, or the US Government Annals of Thoracic Surgery, 1999, 67, 856-857.	0.7	21
181	Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. Journal of Endocrinological Investigation, 1999, 22, 781-789.	1.8	45
182	Prognostic Variables of Papillary Thyroid Carcinomas with Local Invasion Endocrine Journal, 1999, 46, 91-98.	0.7	16
183	Trends in the Clinical Characteristics of Patients with Papillary Thyroid Carcinoma in Taiwan. Oncology, 2000, 58, 280-285.	0.9	10
184	Poorly Differentiated Thyroid Carcinomaâ€"It Is Important. American Journal of Surgical Pathology, 2000, 24, 310.	2.1	33
185	Ablation of the thyroid remnant and 131 I dose in differentiated thyroid cancer. Clinical Endocrinology, 2000, 52, 765-773.	1.2	93

#	Article	IF	CITATIONS
186	Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clinical Endocrinology, 2000, 53, 635-644.	1.2	93
187	Initial treatment of differentiated thyroid carcinoma. , 2000, 1, 139-145.		18
188	Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 833-841.	3.3	141
189	Impact of Initial Surgical Treatment on Survival of Patients with Differentiated Thyroid Cancer: Experience of an Endocrine Surgery Center in an Iodine-deficient Region. World Journal of Surgery, 2000, 24, 1290-1294.	0.8	32
190	Use of Surgical Gamma Probe for the Detection of Lymph Node Metastases in Differentiated Thyroid Cancer. Tumori, 2000, 86, 367-369.	0.6	12
192	Prognostic Value of [18F] Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1107-1113.	1.8	232
194	Papillary Thyroid Carcinoma. Archives of Surgery, 2000, 135, 272.	2.3	110
195	Differentiated thyroid cancer: Clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. Journal of Pediatric Surgery, 2000, 35, 955-960.	0.8	161
196	Long-term relapses of breast cancer: a neglected but important issue. Medical Hypotheses, 2000, 54, 425-426.	0.8	1
197	Preface. Current Pharmaceutical Design, 2000, 6, 1085-1121.	0.9	58
198	45 Morbidity in patients (pts) treated with 1131 metabolic therapy and external beam radiotherapy (ebrt) after thyroidectomy for thyroid differentiated carcinoma. First part: acute toxicity. Radiotherapy and Oncology, 2000, 57, S45-S46.	0.3	0
199	Solitary follicular thyroid carcinoma of the skull base and its differentiation from ectopic adenoma — review, use of galectin-3 and report of a new case. Clinical Neurology and Neurosurgery, 2000, 102, 149-155.	0.6	29
200	The Sentinel Node Procedure with Patent Blue V Dye in the Surgical Treatment of Papillary Thyroid Carcinoma. Acta Oto-Laryngologica, 2001, 121, 421-424.	0.3	51
201	Authors' Response: Metabolic Abnormalities in Patients with Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 951-952.	1.8	1
202	Author's Response: Dietary Protein and Fiber Intake and Sex Hormone-Binding Globulin. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 950-950.	1.8	0
203	Effect of protracted estrogen administration on the thyroid of Ames dwarf mice. Cell and Tissue Research, 2001, 304, 51-58.	1.5	3
204	Differentiated thyroid carcinoma in the elderly. Critical Reviews in Oncology/Hematology, 2001, 38, 79-91.	2.0	24
205	A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer, 2001, 91, 505-524.	2.0	209

#	Article	IF	CITATIONS
207	Recurrent Papillary Thyroid Cancer: Analysis of Prognostic Factors Including the Histological Variant. The European Journal of Surgery, 2001, 167, 406-412.	1.0	26
208	CCN Proteins Are Distinct from, and Should Not Be Considered Members of, the Insulin-Like Growth Factor-Binding Protein Superfamily. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 944-945.	1.8	33
209	Infiltration of Differentiated Thyroid Carcinoma by Proliferating Lymphocytes Is Associated with Improved Disease-Free Survival for Children and Young Adults 1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1346-1354.	1.8	76
210	Prognostic Factors in Well-Differentiated Follicular-Derived Carcinoma and Medullary Thyroid Carcinoma. Thyroid, 2001, 11, 637-645.	2.4	63
211	Paraneoplastic Hypercortisolism as a Risk Factor for Severe Infections in Patients with Malignant Diseases. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 947-948.	1.8	3
212	Hashimoto's Encephalitis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 947-947.	1.8	12
213	CCN Proteins Are Distinct from, and Should Not Be Considered Members of, the Insulin-Like Growth Factor-Binding Protein Superfamily. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 950-950.	1.8	1
214	Metabolic Abnormalities in Patients with Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 950-951.	1.8	3
215	Authors' Response: Usefulness of the Diagnostic Total Body Scan in Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 949-950.	1.8	3
216	Nomenclature of the Insulin-Like Growth Factor-Binding Protein Superfamily. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 946-946.	1.8	6
217	Author's Response: Is Hydrocortisone Clearance 50% Slower in the Evening Than in the Morning?. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 948-949.	1.8	1
218	Leptin Actions on the Reproductive Axis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 946-947.	1.8	6
219	Prognostic Significance of Magnetic Resonance Findings in Advanced Papillary Thyroid Cancer. Thyroid, 2001, 11, 1153-1159.	2.4	17
220	Current Controversies in the Management of Pediatric Patients with Well-Differentiated Nonmedullary Thyroid Cancer: A Review. Thyroid, 2002, 12, 683-702.	2.4	189
221	Characteristics of Follicular Cell-Derived Thyroid Carcinomas Occurring After External Radiation Exposure: Results of a Case Control Study Nested in a Cohort. Thyroid, 2002, 12, 299-304.	2.4	26
222	Death from Differentiated Thyroid Carcinoma: Retrospective Study of a 40-Year Investigation. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 507-514.	0.7	13
223	Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hýrthle cell and papillary thyroid carcinoma. Pathology, 2002, 34, 239-244.	0.3	26
224	Overexpression of Cyclin D1 and Underexpression of p27 Predict Lymph Node Metastases in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1814-1818.	1.8	126

#	Article	IF	CITATIONS
226	Highly Sensitive Serum Thyroglobulin and Circulating Thyroglobulin mRNA Evaluations in the Management of Patients with Differentiated Thyroid Cancer in Apparent Remission. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3201-3208.	1.8	43
227	Thyroid Cancer: A Unique Human Neoplasm. Acta Oto-Laryngologica, 2002, 122, 343-347.	0.3	5
228	Thyroid Carcinomas With Distant Metastases. American Journal of Surgical Pathology, 2002, 26, 1007-1015.	2.1	60
229	Section 2. Thyroid. Biomedicine and Pharmacotherapy, 2002, 56, 83-87.	2.5	6
230	Distribution of lymph node micrometastasis in pNO well-differentiated thyroid carcinoma. Surgery, 2002, 131, 249-256.	1.0	237
231	The role of operations for distantly metastatic well-differentiated thyroid carcinoma. Surgery, 2002, 131, 636-643.	1.0	61
232	Minimally invasive video-assisted thyroidectomy and lymphadenectomy for micropapillary carcinoma of the thyroid. Journal of Surgical Oncology, 2002, 80, 218-221.	0.8	30
233	Differentiated thyroid carcinoma: Comparison between papillary and follicular carcinoma in a single institute. Head and Neck, 2002, 24, 670-677.	0.9	56
234	Radioiodine therapy for papillary and follicular thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, S479-S485.	3.3	45
235	Pattern of Nodal Metastasis for Primary and Reoperative Thyroid Cancer. World Journal of Surgery, 2002, 26, 22-28.	0.8	455
236	Metastatic Differentiated Thyroid Carcinoma: ClinicopathologicalProfile and Outcome in an Iodine Deficient Area. World Journal of Surgery, 2002, 26, 153-157.	0.8	31
237	Importance of Lymph Node Metastases in Follicular Thyroid Cancer. World Journal of Surgery, 2002, 26, 1017-1022.	0.8	69
238	Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. British Journal of Surgery, 2002, 88, 1241-1244.	0.1	171
239	Testicular dose and fertility in men following I131 therapy for thyroid cancer. Clinical Endocrinology, 2002, 56, 755-758.	1.2	134
240	Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 52, 784-795.	0.4	122
241	Detection of Sentinel Lymph Nodes in Patients with Papillary Thyroid Cancer. Asian Journal of Surgery, 2003, 26, 145-148.	0.2	27
242	Long-term results in elderly patients with differentiated thyroid carcinoma. Cancer, 2003, 97, 2736-2742.	2.0	89
243	Papillary microcarcinoma of the thyroid?Prognostic significance of lymph node metastasis and multifocality. Cancer, 2003, 98, 31-40.	2.0	651

#	Article	IF	CITATIONS
244	Incidence and survival of Swedish patients with differentiated thyroid cancer. International Journal of Cancer, 2003, 106, 569-573.	2.3	71
245	Value of external irradiation for locally advanced papillary thyroid cancer. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1006-1012.	0.4	7 3
246	Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer. Clinical Endocrinology, 2003, 58, 451-455.	1.2	15
248	Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery, 2003, 134, 946-954.	1.0	480
249	Long-term relapses of breast cancer: a working hypothesis. Medical Hypotheses, 2003, 61, 398-400.	0.8	1
251	Tumor Size and Extent of Disease at Diagnosis Predict the Response to Initial Therapy for Papillary Thyroid Carcinoma in Children and Adolescents. Journal of Pediatric Endocrinology and Metabolism, 2003, 16, 693-702.	0.4	28
252	Treatment of Recurrent Papillary Thyroid Carcinoma in Children and Adolescents. Journal of Pediatric Endocrinology and Metabolism, 2003, 16, 1033-40.	0.4	11
253	Follicular Carcinoma of the Thyroid. , 2003, 8, 4-15.		1
255	Management and Outcome of Recurrent Well-Differentiated Thyroid Carcinoma. JAMA Otolaryngology, 2004, 130, 819.	1.5	88
256	Radioiodine Dose for Remnant Ablation in Differentiated Thyroid Carcinoma: A Randomized Clinical Trial in 509 Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1666-1673.	1.8	155
257	Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region Endocrine-Related Cancer, 2004, 11, 131-139.	1.6	131
258	The MACIS Score Predicts the Clinical Course of Papillary Thyroid Carcinoma in Children and Adolescents. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 339-43.	0.4	28
259	Prognostic Factors Associated with the Survival of Patients Developing Loco-Regional Recurrences of Differentiated Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5362-5368.	1.8	109
260	Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clinical Endocrinology, 2004, 61, 61-74.	1.2	165
261	Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology, 2004, 44, 490-497.	1.6	42
262	Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?. British Journal of Cancer, 2004, 91, 200-204.	2.9	22
263	Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer. Laryngoscope, 2004, 114, 393-402.	1.1	177
264	Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery, 2004, 136, 1183-1191.	1.0	89

#	Article	IF	CITATIONS
265	lodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 825-830.	3.3	74
266	The management of advanced thyroid cancer. Clinical Oncology, 2004, 16, 561-568.	0.6	45
267	Changing Trends of Incidence and Prognosis of Thyroid Carcinoma in Lower Franconia, Germany, from 1981–1995. Thyroid, 2004, 14, 141-147.	2.4	84
268	Surgical Management of Thyroid Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 458-466.	2.3	19
269	Expression of bcl-2 in Papillary Thyroid Cancers and its Prognostic Value. Acta Chirurgica Belgica, 2005, 105, 644-648.	0.2	16
270	Prognostic Importance of Histologic Vascular Invasion in Papillary Thyroid Carcinoma. Annals of Surgery, 2005, 241, 640-646.	2.1	89
271	High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring. International Journal of Radiation Oncology Biology Physics, 2005, 63, 449-455.	0.4	51
272	Cancers de la thyroïde. EMC - Endocrinologie, 2005, 2, 1-38.	0.0	20
273	Liver Metastasis from Thyroid Carcinoma 32 Years After Resection of the Primary Tumor: Report of a Case. Surgery Today, 2005, 35, 480-482.	0.7	18
274	Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clinical Endocrinology, 2005, 62, 376-379.	1.2	49
275	A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. Journal of the American College of Surgeons, 2005, 200, 378-392.	0.2	44
276	Multifactorial study of prognostic factors in differentiated thyroid carcinoma and a re-evaluation of the importance of age. British Journal of Surgery, 2005, 73, 274-277.	0.1	62
278	Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5723-5729.	1.8	504
279	Diagnosis and Therapeutic Strategy for Papillary Thyroid Microcarcinoma. Archives of Surgery, 2005, 140, 940.	2.3	44
280	Is Patient's Age a Prognostic Factor for Follicular Thyroid Carcinoma in the TNM Classification System?. Thyroid, 2005, 15, 439-448.	2.4	41
281	Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocrine-Related Cancer, 2005, 12, 773-803.	1.6	160
282	Prognostic Factors in Papillary Thyroid Cancer: An Evaluation of 601 Consecutive Patients. Tumor Biology, 2005, 26, 57-64.	0.8	79
283	Immunohistochemical Expression of Bcl-2, Ki-67, and p21 in Patients with Papillary Thyroid Cancer. Tumor Biology, 2005, 26, 50-56.	0.8	26

#	Article	IF	Citations
284	Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology, 2005, 153, 651-659.	1.9	174
285	Papillary thyroid microcarcinoma: A surgical perspective. Cancer Treatment Reviews, 2005, 31, 423-438.	3.4	117
286	Transplant recipients with a history of a malignancy: risk of recurrent and de novo cancers. Transplantation Reviews, 2005, 19, 55-64.	1.2	32
287	Contemporary management of thyroid cancer. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2005, 26, 249-260.	0.6	29
289	Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer. Journal of Endocrinological Investigation, 2006, 29, 131-135.	1.8	27
290	Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer. , 2006, , 149-163.		2
291	Chapter 4 Controversies in the use of radioiodine for remnant ablation and therapy of thyroid carcinoma. Advances in Molecular and Cellular Endocrinology, 2006, , 49-82.	0.1	0
292	Late Disease Recurrence in Patients Diagnosed With and Treated for Differentiated Thyroid Carcinoma. , 2006, 16, 329-334.		1
293	Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1299-1307.	0.4	9
294	Sentinel Lymph Node Biopsy May Be Used to Support the Decision to Perform Modified Radical Neck Dissection in Differentiated Thyroid Carcinoma. World Journal of Surgery, 2006, 30, 841-846.	0.8	53
295	Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. Journal of Surgical Oncology, 2006, 94, 692-700.	0.8	90
296	Treatment of thyroid cancer based on risk groups. Journal of Surgical Oncology, 2006, 94, 683-691.	0.8	69
297	A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy. Acta Oncol \tilde{A}^3 gica, 2006, 45, 1067-1072.	0.8	18
298	VEGF-C and COX-2 expression in papillary thyroid cancer. Endocrine-Related Cancer, 2006, 13, 465-473.	1.6	36
299	Survival and Death Causes in Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 313-319.	1.8	248
300	Detection and Surgical Treatment of Cervical Lymph Nodes in Differentiated Thyroid Cancer. Thyroid, 2006, 16, 187-194.	2.4	56
301	Papillary and Follicular Thyroid Cancers in Children. , 2007, 10, 140-172.		11
302	Percutaneous Ethanol Injection Therapy for Locally Recurrent Papillary Thyroid Carcinoma. Thyroid, 2007, 17, 347-350.	2.4	81

#	Article	IF	CITATIONS
303	Differentiated Thyroid Carcinoma with Distant Metastases: Probability of Survival and Its Predicting Factors. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 250-255.	0.7	47
304	Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 399-409.	0.9	7
305	Use of preoperative lymphoscintigraphy and intraoperative gamma-probe detection for identification of the sentinel lymph node in patients with papillary thyroid carcinoma. European Journal of Surgical Oncology, 2007, 33, 1075-1080.	0.5	47
306	New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncology, The, 2007, 8, 148-156.	5.1	136
307	Prognostic factors determining survival in differentiated thyroid cancer. Journal of Surgical Oncology, 2007, 96, 598-604.	0.8	41
308	Prognostic Factors in Papillary and Follicular Thyroid Carcinoma: Their Implications for Cancer Staging. Annals of Surgical Oncology, 2007, 14, 730-738.	0.7	119
309	Mitochondrial DNA Mutations in Differentiated Thyroid Cancer with Respect to the Age Factor. World Journal of Surgery, 2007, 31, 51-59.	0.8	14
310	Lateral and Mediastinal Lymph Node Dissection in Differentiated Thyroid Carcinoma: Indications, Benefits, and Risks. World Journal of Surgery, 2007, 31, 905-915.	0.8	90
311	TNM Classification of Thyroid Carcinoma. World Journal of Surgery, 2007, 31, 879-887.	0.8	102
312	Efficacy of Nodal Dissection for Treatment of Persistent/Recurrent Papillary Thyroid Cancer. Laryngoscope, 2008, 118, 768-775.	1.1	76
313	Papillary Thyroid Cancer: Controversies in the Management of Neck Metastasis. Laryngoscope, 2008, 118, 2161-2165.	1.1	72
314	Airway stenting for the treatment of laryngotracheal stenosis secondary to thyroid cancer. Respirology, 2008, 13, 632-638.	1.3	22
315	Approach to the Patient with a Positive Serum Thyroglobulin and a Negative Radioiodine Scan after Initial Therapy for Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1519-1525.	1.8	46
316	Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 1009-1021.	2.2	45
317	Management of Locally Invasive Well-Differentiated Thyroid Cancer. Surgical Oncology Clinics of North America, 2008, 17, 145-155.	0.6	19
318	Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma European Journal of Endocrinology, 2008, 158, 551-560.	1.9	164
319	Molecular analysis of multifocal papillary thyroid carcinoma. Journal of Molecular Endocrinology, 2008, 41, 195-203.	1.1	59
320	Malignant Struma Ovarii: Good Response after Thyroidectomy and 131I Ablation Therapy. Clinical Medicine Oncology, 2008, 2, CMO.S410.	0.2	25

#	Article	IF	CITATIONS
321	Imaging for staging and management of thyroid cancer. Cancer Imaging, 2008, 8, 57-69.	1.2	43
322	Prognostic Factors in Patients with Multiple Recurrences of Well-Differentiated Thyroid Carcinoma. Journal of Oncology, 2009, 2009, 1-6.	0.6	8
323	Thyroid and Parathyroid., 2009,, 1597-1685.		12
324	Targeted molecular therapies in thyroid carcinoma. Arquivos Brasileiros De Endocrinologia E Metabologia, 2009, 53, 1061-1073.	1.3	11
325	Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances. Thyroid, 2009, 19, 1393-1400.	2.4	80
326	Preoperative Staging of Papillary Thyroid Carcinoma: Comparison of Ultrasound Imaging and CT. American Journal of Roentgenology, 2009, 193, 871-878.	1.0	279
327	Altered Chemokine Receptor Expression in Papillary Thyroid Cancer. Thyroid, 2009, 19, 957-965.	2.4	21
328	Routine pre-operative ultrasonography for papillary thyroid cancer: Effects on cervical recurrence. Surgery, 2009, 146, 1063-1072.	1.0	47
329	Classification of follicular cell tumors of the thyroid gland: Analysis involving Japanese patients from one institute. Pathology International, 2009, 59, 359-367.	0.6	50
330	Central lymph node metastases in unilateral papillary thyroid microcarcinoma. British Journal of Surgery, 2009, 96, 253-257.	0.1	125
331	Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 343-346.	3.3	35
332	Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer. Clinical Endocrinology, 2009, 71, 880-883.	1.2	11
333	Clinical and Pathological Factors Related to 18F-FDG-PET Positivity in the Diagnosis of Recurrence and/or Metastasis in Patients with Differentiated Thyroid Cancer. Annals of Surgical Oncology, 2009, 16, 2006-2013.	0.7	29
334	Solitary Lung Metastasis Diagnosed 30 Years After Surgery for Thyroid Cancer. Annals of Thoracic Surgery, 2009, 88, 2016-2017.	0.7	6
335	Follicular Thyroid Carcinoma in an Iodine-Replete Endemic Goiter Region. Annals of Surgery, 2009, 249, 1023-1031.	2.1	91
336	Total Thyroidectomy Followed by Postsurgical Remnant Ablation May Improve Cancer Specific Survival in Differentiated Thyroid Carcinoma. Clinical Nuclear Medicine, 2010, 35, 396-399.	0.7	13
337	Combination of Preoperative Ultrasonographic Mapping and Radioguided Occult Lesion Localization in Patients With Locally Recurrent/Persistent Papillary Thyroid Carcinoma. Clinical Nuclear Medicine, 2010, 35, 847-852.	0.7	26
338	Spontaneous regression of malignant tumors: Importance of the immune system and other factors (Review). Oncology Letters, 2010, 1, 941-945.	0.8	56

#	ARTICLE	IF	CITATIONS
339	Detection of Residual Lymph Node Metastases in High-Risk Papillary Thyroid Cancer Patients Receiving Adjuvant I-131 Therapy. Clinical Nuclear Medicine, 2010, 35, 6-11.	0.7	14
340	Management of thyroid cancers. Indian Journal of Surgical Oncology, 2010, 1, 151-162.	0.3	1
341	Radioiodine Therapy in Differentiated Thyroid Cancer: a Nuclear Medicine Perspective. Clinical Oncology, 2010, 22, 430-437.	0.6	11
342	An Evaluation of Lymph Node Yield and Lymph Node Ratio in Well-Differentiated Thyroid Carcinoma. American Surgeon, 2010, 76, 28-32.	0.4	57
343	Postoperative Management of Differentiated Thyroid Cancer. Otolaryngologic Clinics of North America, 2010, 43, 329-351.	0.5	5
344	Follicular thyroid carcinoma invades venous rather than lymphatic vessels. Diagnostic Pathology, 2010, 5, 8.	0.9	23
345	A new radioguided procedure for localization and surgical treatment of neck node metastasis of papillary thyroid cancer. Journal of Endocrinological Investigation, 2010, 33, 339-342.	1.8	10
346	Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Molecular and Cellular Endocrinology, 2010, 322, 8-28.	1.6	114
347	Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. Clinical Investigation, 2011, 1, 241-253.	0.0	3
348	Good practice guide for cervical ultrasound scan and echo-guided techniques in treating differentiated thyroid cancer of vesicular origin. Annales D'Endocrinologie, 2011, 72, 173-197.	0.6	27
350	Clinical significance of residual occult malignancy in thyroid carcinoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2011, 32, 398-401.	0.6	15
351	Radioiodine for remnant ablation and therapy of metastatic disease. Nature Reviews Endocrinology, 2011, 7, 589-595.	4.3	56
352	Molecular nuclear therapies for thyroid carcinoma. Methods, 2011, 55, 230-237.	1.9	13
353	The Role of Prophylactic Central Neck Dissection in Differentiated Thyroid Carcinoma: Issues and Controversies. Journal of Oncology, 2011, 2011, 1-12.	0.6	21
354	Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. Surgery, 2011, 150, 1258-1265.	1.0	35
355	Staging of Papillary Thyroid Carcinoma with Ultrasonography: Performance in a Large Series. Annals of Surgical Oncology, 2011, 18, 3572-3578.	0.7	45
356	The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 265-276.	1.4	47
357	Adjuvant Radioactive Therapy after Reoperation for Locoregionally Recurrent Papillary Thyroid Cancer in Patients Who Initially Underwent Total Thyroidectomy and High-Dose Remnant Ablation. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3695-3700.	1.8	33

#	Article	IF	CITATIONS
358	Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine) Tj ETQq0 0 0 rgBT of Endocrinology, 2011, 165, 441-446.	/Overlock 1.9	10 Tf 50 74 243
359	The Outcomes of First Reoperation for Locoregionally Recurrent/Persistent Papillary Thyroid Carcinoma in Patients Who Initially Underwent Total Thyroidectomy and Remnant Ablation. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2049-2056.	1.8	105
360	ACR–ASTRO Practice Guideline for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. Clinical Nuclear Medicine, 2011, 36, e72-e80.	0.7	5
361	Suspicious Cervical Lymph Nodes Detected after Thyroidectomy for Papillary Thyroid Cancer Usually Remain Stable Over Years in Properly Selected Patients. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2706-2713.	1.8	127
362	Terminology inaccuracies in the interpretation of imaging results in detection of cervical lymph node metastases in papillary thyroid cancer. Endocrine Connections, 2012, 1, 78-86.	0.8	7
363	Long-Term Clinical Outcome of Differentiated Thyroid Cancer Patients with Undetectable Stimulated Thyroglobulin Level One Year After Initial Treatment. Thyroid, 2012, 22, 784-790.	2.4	58
364	Sociodemographic Predictors of Survival in Differentiated Thyroid Cancer: Results from the SEER Database. Isrn Endocrinology, 2012, 2012, 1-8.	2.0	20
365	Analysis of prognostic factors in patients with multiple recurrences of papillary thyroid carcinoma. Surgical Oncology, 2012, 21, 185-190.	0.8	26
366	The Impact of Age and Gender on Papillary Thyroid Cancer Survival. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E878-E887.	1.8	162
367	To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients. Journal of Oncology, 2012, 2012, 1-11.	0.6	28
368	Managing Thyroid Microcarcinomas. Yonsei Medical Journal, 2012, 53, 1.	0.9	32
369	18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1373-1380.	3.3	68
370	TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 587-600.	1.4	42
371	Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. Head and Neck, 2013, 35, 592-598.	0.9	30
372	Preoperative Prediction of Central Lymph Node Metastasis in Thyroid Papillary Microcarcinoma Using Clinicopathologic and Sonographic Features. World Journal of Surgery, 2013, 37, 385-391.	0.8	95
373	Thyroid remnant ablation in differentiated thyroid carcinoma: when and how. Clinical and Translational Imaging, 2013, $1,195$ -203.	1.1	O
374	Pattern of Spread to the Lateral Neck in Metastatic Well-Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. Thyroid, 2013, 23, 583-592.	2.4	76
375	Thyroid and Parathyroid Tumors. , 2013, , 297-361.		О

#	Article	IF	CITATIONS
376	Metastatic papillary thyroid cancer with lateral neck disease: Pattern of spread by level. Head and Neck, 2013, 35, 1439-1442.	0.9	19
377	Preoperative Ultrasonographic Features of Papillary Thyroid Carcinoma Predict Biological Behavior. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1476-1482.	1.8	75
378	How reliable is secondary risk stratification with stimulated thyroglobulin in patients with differentiated thyroid carcinoma?. Nuklearmedizin - NuclearMedicine, 2013, 52, 88-96.	0.3	5
379	CD3 ^{â^'} CD16 ^{â^'} CD56 ^{bright} Immunoregulatory NK Cells are Increased in the Tumor Microenvironment and Inversely Correlate with Advanced Stages in Patients with Papillary Thyroid Cancer. Thyroid, 2013, 23, 1561-1568.	2.4	56
380	Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings. Endocrine Journal, 2013, 60, 291-297.	0.7	12
381	Regional Differences in Thyroid Cancer Presentation and Survival: a Seer Study. Endocrine Practice, 2013, 19, 998-1006.	1.1	7
382	New insights in risk stratification of differentiated thyroid cancer. Current Opinion in Oncology, 2014, 26, 1-7.	1.1	17
383	Postoperative radioactive iodine administration for differentiated thyroid cancer patients. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 363-371.	1.2	19
384	Thyroid cancer. Current Problems in Cancer, 2014, 38, 48-74.	1.0	36
385	Lobectomy and Prophylactic Central Neck Dissection for Papillary Thyroid Microcarcinoma: Do Involved Lymph Nodes Mandate Completion Thyroidectomy?. World Journal of Surgery, 2014, 38, 872-877.	0.8	21
386	SIN1, a critical component of theÂmTOR-Rictor complex, is overexpressed and associated with AKTÂactivation in medullary and aggressive papillary thyroid carcinomas. Surgery, 2014, 156, 1542-1549.	1.0	14
387	Clinical, Pathologic, and Immunohistochemical Prognostic Factors in Dogs with Thyroid Carcinoma. Journal of Veterinary Internal Medicine, 2014, 28, 1805-1813.	0.6	48
388	Differentiated thyroid cancerâ€"personalized therapies to prevent overtreatment. Nature Reviews Endocrinology, 2014, 10, 563-574.	4.3	30
389	Guidelines for the management of thyroid cancer. Clinical Endocrinology, 2014, 81, 1-122.	1.2	961
390	Treatment Approach, Surveillance, and Outcome of Well-Differentiated Thyroid Cancer in Childhood and Adolescence. Thyroid, 2014, 24, 1121-1126.	2.4	79
392	Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: A prospective study on 345 patients with a 3-year follow-up. Surgery, 2014, 156, 147-157.	1.0	24
393	Biomarkers in Myelodysplastic Syndrome. , 2014, , 807-836.		0
395	Differentiated Thyroid Cancer With Liver Metastases: Lessons Learned From Managing a Series of 14 Patients. International Surgery, 2015, 100, 490-496.	0.0	11

#	ARTICLE	IF	CITATIONS
396	The Prognostic Significance of the Metastatic Lymph Node Ratio in Patients with Papillary Thyroid Carcinoma. The Korean Journal of Endocrine Surgery, 2015, 15, 67.	0.1	O
397	Prediction of Nodal Metastasis by the AMES Scoring System in Patients with Papillary Thyroid Cancer. The Korean Journal of Endocrine Surgery, 2015, 15, 86.	0.1	0
398	Association of Preoperative US Features and Recurrence in Patients with Classic Papillary Thyroid Carcinoma. Radiology, 2015, 277, 574-583.	3.6	47
399	The Significance of Cervical Lymph Nodes in Well-Differentiated Thyroid Cancer. Head and Neck Cancer Clinics, 2015, , 15-27.	0.0	0
400	Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. PET Clinics, 2015, 10, 265-278.	1.5	20
401	Management of Thyroid Cancer. Head and Neck Cancer Clinics, 2015, , .	0.0	1
402	Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid, 2015, 25, 1097-1105.	2.4	20
404	The influence of body mass index on the diagnostic performance of preâ€operative staging ultrasound in papillary thyroid carcinoma. Clinical Endocrinology, 2015, 83, 550-555.	1.2	14
405	Impact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 115-121.	1.8	90
406	Outcome of Well-Differentiated Thyroid Carcinoma Patients Receiving a Cumulative Doses of ? 600 mCi (22GBq) of I-131. Bangladesh Journal of Nuclear Medicine, 2016, 17, 114-119.	0.0	1
407	Impact of patient age on the iodine/FDG "flip-flop―phenomenon in lung metastasis from thyroid cancer. Annals of Nuclear Medicine, 2016, 30, 518-524.	1.2	12
408	Differentiated thyroid cancer in patients ≥75 years: Histopathological features and results of surgical treatment. International Journal of Surgery, 2016, 33, S159-S163.	1.1	14
409	BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma. Head and Neck, 2016, 38, 1017-1021.	0.9	8
410	Ultrasoundâ€based clinical prediction rule model for detecting papillary thyroid cancer in cervical lymph nodes: A pilot study. Journal of Clinical Ultrasound, 2016, 44, 143-151.	0.4	13
411	The Role of SPECT/CT Lymphoscintigraphy and Radioguided Sentinel Lymph Node Biopsy in Managing Papillary Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 834.	1.2	24
412	Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3036-3044.	1.8	54
413	Shear-Wave Elastography for Papillary Thyroid Carcinoma can Improve Prediction of Cervical Lymph Node Metastasis. Annals of Surgical Oncology, 2016, 23, 722-729.	0.7	24
414	The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice. European Journal of Endocrinology, 2016, 175, 379-385.	1.9	10

#	Article	IF	CITATIONS
416	Surgery of the Thyroid Glands. , 2016, , 225-333.		0
417	Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer. European Journal of Endocrinology, 2016, 174, 373-380.	1.9	50
418	Should central lymph node dissection be considered for all papillary thyroid microcarcinoma?. Asian Journal of Surgery, 2016, 39, 197-201.	0.2	40
419	Thyroid Neoplasia. , 2016, , 1601-1628.e10.		1
420	Lymph node characteristics for predicting locoregional recurrence of papillary thyroid cancer in adolescents and young adults. Oral Oncology, 2017, 66, 22-27.	0.8	14
421	A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocrine Connections, 2017, 6, R8-R17.	0.8	68
422	Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells. Endocrine-Related Cancer, 2017, 24, 147-156.	1.6	28
423	The utility of intraâ€operative frozen section for the evaluation of microscopic extrathyroidal extension in papillary thyroid carcinoma. Clinical Otolaryngology, 2017, 42, 1167-1171.	0.6	5
424	Development of a New Clinical Severity Staging System for Patients With Nonmetastatic Papillary Thyroid Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1173.	1.2	12
425	Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification. Thyroid, 2017, 27, 778-786.	2.4	13
426	Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 926-934.	3.3	17
427	Significance of micrometastases in the calculation of the lymph node ratio for papillary thyroid cancer. Annals of Surgical Treatment and Research, 2017, 92, 117.	0.4	9
428	Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer With Locoregional Persistent Disease. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 469-476.	1.8	19
429	Differentiated Thyroid Cancer: Diagnosis, Therapy, and Follow-Up. , 2018, , 51-64.		0
430	Comparison of the diagnostic performances of ultrasonography, CT and fine needle aspiration cytology for the prediction of lymph node metastasis in patients with lymph node dissection of papillary thyroid carcinoma: A retrospective cohort study. International Journal of Surgery, 2018, 51, 145-150.	1.1	30
431	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	0.8	58
432	Relationship between ultrasonographic and pathologic calcification patterns in papillary thyroid cancer. Medicine (United States), 2018, 97, e12675.	0.4	17
433	Differentiated thyroid cancer theranostics: radioiodine and beyond. British Journal of Radiology, 2018, 91, 20180136.	1.0	68

#	Article	IF	CITATIONS
434	Comparison of outcomes between hemithyroidectomy alone and hemithyroidectomy with elective unilateral central neck dissection in patients with papillary thyroid microcarcinoma. Head and Neck, 2018, 40, 2449-2454.	0.9	10
435	Refining definitions within lowâ€risk differentiated thyroid cancers. Clinical Otolaryngology, 2018, 43, 1195-1200.	0.6	3
436	Clinicopathological significance of cancer-associated fibroblasts in papillary thyroid carcinoma: a predictive marker of cervical lymph node metastasis. European Archives of Oto-Rhino-Laryngology, 2018, 275, 2355-2361.	0.8	26
437	The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. OncoTargets and Therapy, 2018, Volume 11, 3551-3560.	1.0	19
438	Clinic-pathologic Features and Prognostic Analysis of Thyroid Cancer in the Older Adult: A SEER Based Study. Journal of Cancer, 2018, 9, 2744-2750.	1.2	19
439	Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells. International Journal of Oncology, 2019, 55, 7-20.	1.4	9
440	Obes every classical type of well-differentiated thyroid cancer have excellent prognosis? A case series and literature review. Cancer Management and Research, 2019, Volume 11, 2441-2448.	0.9	6
441	Radioiodine Therapy of Thyroid Cancer. , 2019, , 35-42.		0
442	Nuclear Medicine Therapy. , 2019, , .		5
443	Relationship between Initial Thyroid Operation and the Location of Locoregional Recurrence in Papillary Thyroid Cancer: a Single Tertiary Center Experience. Journal of Endocrine Surgery, 2019, 19, 116.	0.0	0
444	Current trends in the features of male thyroid cancer. Medicine (United States), 2019, 98, e15559.	0.4	15
445	Nomogram for predicting level V lymph node metastases in papillary thyroid carcinoma with clinically lateral lymph node metastases: A large retrospective cohort study of 1037 patients from FDUSCC. Journal of Cancer, 2019, 10, 772-778.	1.2	17
446	Role of 18F-FDG-PET/CT in patients with differentiated thyroid cancer with biochemical incomplete or indeterminate response to treatment. Endocrinologia, Diabetes Y NutriciÓn, 2020, 67, 517-524.	0.1	4
447	Role of 18F-FDG-PET/CT in patients with differentiated thyroid cancer with biochemical incomplete or indeterminate response to treatment. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2020, 67, 517-524.	0.1	0
448	An Animal Model Further Uncovers the Role of Mutant Braf during Papillary ThyroidÂCancer Development. American Journal of Pathology, 2020, 190, 702-710.	1.9	1
449	Current practice in patients with differentiated thyroid cancer. Nature Reviews Endocrinology, 2021, 17, 176-188.	4.3	161
450	Predictive value of the Delphian lymph node in cervical lymph node metastasis of papillary thyroid carcinoma. European Journal of Surgical Oncology, 2021, 47, 1727-1733.	0.5	11
451	External radiotherapy in thyroid cancers. Cancer, 1985, 55, 2062-2071.	2.0	143

#	Article	IF	CITATIONS
452	Thyroid Cancer: Impact of Therapeutic Modalities on Prognosis. Growth Hormone, 1998, , 255-284.	0.2	9
453	Thyroid Carcinoma. , 2006, , 497-508.		3
454	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. , 2017, , 545-583.		1
455	SchilddrÃ1/4se., 2016, , 631-712.		9
456	Surgical Strategies in Papillary Thyroid Carcinoma. Current Topics in Pathology Ergebnisse Der Pathologie, 1997, 91, 51-64.	0.2	6
457	Apoptosis and Proliferative Activity in Thyroid Tumors. Surgery Today, 1999, 29, 204-208.	0.7	9
458	Management of Thyroid Neoplasms. , 2010, , 1750-1772.		8
459	Thyroid gland., 2011,, 487-564.		59
460	The Treatment of Metastatic Thyroid Disease. Otolaryngologic Clinics of North America, 1990, 23, 475-493.	0.5	22
461	Radioiodine and Radiotherapy in the Management of Thyroid Cancers. Otolaryngologic Clinics of North America, 1990, 23, 509-521.	0.5	39
462	Diagnosis and Management of the Thyroid Nodule. Otolaryngologic Clinics of North America, 1990, 23, 303-337.	0.5	31
463	Factors that Predict Metastasis of Papillary and Follicular Thyroid Cancers in Taiwan. Otolaryngology - Head and Neck Surgery, 1997, 116, 475-482.	1.1	2
464	Radioiodsne-131 In the Diagnosis and Treatment of Metastatic Weil Differentiated Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 1990, 19, 685-718.	1.2	359
465	Clinical Presentations and Treatment for 74 Occult Thyroid Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 504-508.	0.6	27
466	Estrogen-Receptor Status of Patients Who Underwent Mastectomy for Breast Cancer With a Disease-Free Interval of Not Less Than 8 Years. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 250-252.	0.6	5
467	Differentiated Thyroid Cancer: Determinants of Disease Progression in Patients <21 Years of Age at Diagnosis. Annals of Surgery, 1998, 227, 533-541.	2.1	201
468	Papillary Thyroid Cancer in Saudi Arabia Clinical, Pathologic, and Management Characteristics. Clinical Nuclear Medicine, 1996, 21, 307-311.	0.7	15
469	Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1107-1113.	1.8	269

#	Article	IF	CITATIONS
470	Usefulness of the Diagnostic Total Body Scan in Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 949-949.	1.8	1
471	Clinical prognosis in BRAF-mutated PTC. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 736-747.	1.3	21
472	The Prognostic Significance of the Metastatic Lymph Node Ratio in Patients with Papillary Thyroid Carcinoma. The Korean Journal of Endocrine Surgery, 2015, 15, 67.	0.1	1
473	Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 253-257.	0.4	8
474	Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma. Oncology Letters, 2020, 19, 343-349.	0.8	4
475	Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease. Journal of Postgraduate Medicine, 2007, 53, 23-26.	0.2	68
476	High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting non-remission. Annals of Saudi Medicine, 2008, 28, 277-281.	0.5	6
477	Bone Metastases From Thyroid Carcinoma. Archives of Pathology and Laboratory Medicine, 2000, 124, 1440-1447.	1.2	61
478	Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013. Cureus, 2019, 11, e4127.	0.2	79
479	Tireoidectomia unilateral no carcinoma diferenciado da tire $ ilde{A}^3$ ide de baixo risco: uma cirurgia inadequada. Revista Do Colegio Brasileiro De Cirurgioes, 2001, 28, 181-187.	0.3	1
480	Surgical treatment of a solitary pulmonary metastasis from thyroidcancer resected 12 years earlier The Journal of the Japanese Association for Chest Surgery, 2002, 16, 128-132.	0.0	1
482	Treatment of Locally Advanced Thyroid Cancer. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2004, 47, 1168.	0.1	0
483	Surgical treatment of differentiated thyroid carcinoma: a retrospective study. Frontiers in Bioscience - Landmark, 2006, 11, 2206.	3.0	1
484	Follicular Carcinoma. , 2009, , 383-397.		0
485	Clinical Analysis of Risk Factors Related to Recurrent Well Differentiated Thyroid Carcinoma. Korean Journal of Otolaryngology - Head and Neck Surgery, 2009, 52, 431.	0.1	0
486	Thyroid Neoplasia. , 2010, , 1668-1701.		1
487	Central Neck Dissection., 2012,, 215-221.		1
488	Papillary Thyroid Microcarcinoma - Do Classical Staging Systems Need to Be Changed?., 0, , .		0

#	Article	IF	CITATIONS
489	The long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level at one year after initial treatment. Thyroid, 0, , 120328072216008.	2.4	0
491	Clinical Aspects of Detection and Imaging of Differentiated Thyroid Tumors., 1986,, 66-73.		0
492	The Ionic Microscope Enables the Visualization of Stable Iodine within Follicles of the Human Thyroid Gland., 1986,, 465-469.		0
493	Therapiekonzepte., 1987,, 1-899.		1
494	Thyroid Cancer and its Management with Radiation Therapy. Medical Radiology, 1989, , 197-210.	0.0	0
495	Evaluation and Medical Management of Thyroid Cancer. Cancer Treatment and Research, 1990, 52, 151-170.	0.2	2
496	MULTIVARIATE STUDY OF PROGNOSTIC FACTORS IN DIFFERENTIATED THYROID CARICNOMAS. The Journal of the Japanese Practical Surgeon Society, 1991, 52, 1413-1419.	0.0	0
497	Surgical Aspects of Diseases of the Thyroid Gland in Childhood. Progress in Pediatric Surgery, 1991, 26, 15-20.	0.3	0
498	Thyroid Cancer in the Pediatric Patient. , 1992, , 45-64.		0
499	External Radiation Treatment for Thyroid Carcinoma. , 1992, , 182-203.		1
501	Follicular Carcinoma of the Thyroid. , 1992, , 16-31.		0
502	Prognostisch relevante Faktoren beim papillÄæn Schilddrüsenkarzinom unter besonderer BerA¼cksichtigung des DNS-Gehalts. , 1993, , 93-106.		0
503	The Radiotherapy and Management of Thyroid Tumours. , 1993, , 277-293.		0
504	Das metastasierende Karzinom im Follow-up. , 1993, , 319-330.		0
505	Thyroid Carcinoma. , 1994, , 279-287.		0
506	A CLINICOPATHOLOGICAL STUDY OF CASES OF DEATHS DUE TO THYROID CANCER. The Journal of the Japanese Practical Surgeon Society, 1995, 56, 480-485.	0.0	0
507	Thyroid Carcinoma. , 1995, , 28-36.		3
508	Towards Understanding the Molecular Basis of Thyroid Cancer. Annals of Saudi Medicine, 1995, 15, 252-275.	0.5	O

#	Article	IF	CITATIONS
509	Thyroid disease., 1998,, 9-25.		1
510	Surgical Experience in the Management of 125 Patients with Thyroid Masses in Kashmir. International Journal of Otolaryngology and Head & Deck Surgery, 2015, 04, 381-393.	0.1	0
511	Factors Affecting Disease-Free Status of Differentiated Thyroid Carcinoma Patients. Asian Pacific Journal of Cancer Prevention, 2015, 16, 737-740.	0.5	1
512	External Radiation Therapy for Follicular Carcinoma. , 2016, , 807-810.		0
513	Radionuclide Therapy of Thyroid Tumors. , 2016, , 1-47.		0
514	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. , 2016, , 1-40.		1
515	Radionuclide Therapy of Thyroid Tumors. , 2017, , 1197-1241.		1
516	Size of Primary Thyroid Tumor is Not a Predictor for Lymph Node Affection in Early Subsequent Recurrence in WDTC. Medical Journal of the University of Cairo Faculty of Medicine, 2018, 86, 2967-2971.	0.0	0
517	Management of Recurrent Lymph Nodes in Central and Lateral Neck in the Follow-Up of Differentiated Thyroid Carcinoma., 2019,, 305-311.		0
518	Schilddrýsenkarzinom., 2019, , 63-67.		0
519	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
520	Hybrid Imaging and Radionuclide Therapy for Thyroid Disorders. , 2019, , 707-747.		0
522	Liver metastasis from papillary thyroid carcinoma treated by laparoscopic hepatectomy 43 years after resection of the primary tumor: a case report. Surgical Case Reports, 2020, 6, 142.	0.2	4
523	Recurrent Thyroid Disease. , 2020, , 457-504.		0
524	Differentiated Thyroid Cancer: Radioiodine Therapy. , 2020, , 831-844.		1
525	Prediction of Nodal Metastasis by the AMES Scoring System in Patients with Papillary Thyroid Cancer. The Korean Journal of Endocrine Surgery, 2015, 15, 86.	0.1	0
526	Predictors of thyroid tumor aggressiveness. Western Journal of Medicine, 1996, 165, 131-8.	0.3	38
527	Pattern of regional metastases and prognostic factors in differentiated thyroid carcinoma. Acta Otorhinolaryngologica Italica, 2009, 29, 312-6.	0.7	15

#	Article	IF	CITATIONS
528	Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?. Cancers, 2022, 14, 501.	1.7	0
531	Thyroid and Adrenal Cancer. , 0, , 350-363.		0
532	Thyroid and Adrenal Cancer., 0,, 374-387.		0
533	Predictive value of metastatic lateral lymph node ratio for recurrence in pathologically lateral lymph nodeâ€positive papillary thyroid cancer patients with palpable lymph nodes. Head and Neck, 2022, , .	0.9	2
536	The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer. Frontiers in Endocrinology, 2022, 13, .	1.5	11
537	Radionuclide Therapy of Thyroid Tumors. , 2022, , 1381-1429.		O
538	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. , 2022, , 643-682.		0
539	A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. Cancers, 2022, 14, 4128.	1.7	8
540	One hundred mostâ€cited articles in head and neck surgery and analysis of female authorship. Head and Neck, 0, , .	0.9	0
541	Comparison of Nuclear DNA Content in Locally Invasive and Noninvasive Papillary Carcinoma of the Thyroid Gland. Otolaryngology - Head and Neck Surgery, 1997, 117, 501-503.	1.1	0
542	Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer. Endocrine Connections, 2022, , .	0.8	0